Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2016-08-05 Regulatory Filings
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings
2016-08-05 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions a press release about a partial clinical hold by the FDA on a clinical trial, and it references a forthcoming conference call to discuss the second quarter results. There are no actual financial statements or detailed financial data included in this document. The document is relatively short (4062 characters) and primarily serves as an announcement of an event and a press release. It does not contain the full earnings release or detailed financial results, nor is it a management discussion or regulatory certification. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like 8-Ks that do not fit other specific categories.
2016-08-04 English
Regulatory Filings 2016
Regulatory Filings Classification · 100% confidence The document is a Form F-6 Registration Statement filed with the SEC, which is used to register American Depositary Shares (ADS) evidenced by American Depositary Receipts (ADR). It includes details about the securities to be registered, the deposit agreement, and signatures of company officers and directors. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration under the Securities Act of 1933. The document length is about 11,898 characters, and it contains the full registration statement text, not just an announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-07-28 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for public offering. It includes a base prospectus describing the terms of American Depositary Shares (ADSs) to be offered up to $250 million. The document contains detailed information about the securities, the offering process, risk factors, and legal matters. It is not a financial report, earnings release, or management discussion, but a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the actual registration statement and prospectus, not just an announcement or notice.
2016-07-28 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or updates by a company. The text includes detailed management discussion and analysis of financial condition and results of operations, forward-looking statements, significant corporate highlights, clinical developments, and recent developments. It references prior filings such as Form 10-Q and Form 20-F but is itself a standalone current report. The document is not a full annual or quarterly report but a current report providing updates on operations and financial condition. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories such as Annual Report (10-K) or Interim Report (IR). The document length is substantial and contains substantive information, but it is not a full financial report. Hence, the appropriate classification is RNS with high confidence.
2016-07-08 English
3
Director's Dealing
2016-06-23 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.